Ocular Therapeutix (OCUL) Stock: Buy, Sell, or Hold?
OCUL - Ocular Therapeutix, Inc.
$7.29
-0.38 (-4.95%)
▼
5d:
-25.76%
30d:
-31.03%
90d:
-24.38%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When OCUL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OCUL is down 25.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OCUL is down 25.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OCUL is currently trading at $7.29, which is considered oversold relative to its 30-day fair value range of $8.99 to $11.17.
Technical Outlook: Technically, OCUL is in a strong uptrend. The price is currently testing key support at $7.18. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: OCUL scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.09 (+271.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OCUL is in a strong uptrend. The price is currently testing key support at $7.18. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: OCUL scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.09 (+271.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.99 -
$11.17
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding OCUL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 271.6% below Wall St target ($27.09)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.99 -
$11.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.18
Resistance Level
$10.61
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.01
Wall Street Target
$27.09
(+271.6%)
Revenue Growth (YoY)
0.1%
Share & Embed Analysis
Last updated: October 02, 2026 8:32 AM ET
Data refreshes hourly during market hours. Next update: 9:32 AM
Data refreshes hourly during market hours. Next update: 9:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCUL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
Advanced OCUL Option Strategies
Professional options setups generated by AI based on today's OCUL price and gamma walls.
